Welcome to our dedicated page for Immix Biopharma SEC filings (Ticker: IMMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immix Biopharma, Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company with common stock registered under ticker IMMX and a development program centered on NXC-201 for relapsed/refractory AL Amyloidosis. Current reports include Regulation FD and other-event disclosures for NEXICART-2 clinical updates and regulatory-development matters.
The company’s SEC record also covers capital-structure activity, including at-the-market sales agreements, shelf registration statements, registered offerings, private placements, warrants and resale registration rights. Proxy materials disclose director elections, auditor ratification, annual-meeting voting results and other governance matters.
Immix Biopharma director Nancy T. Chang reported new equity awards, not open‑market trades. She received 6,250 restricted stock units under the 2021 Equity Incentive Plan, which vest in full on the earlier of the one-year anniversary of grant or the company’s 2027 annual stockholders’ meeting, subject to continued service.
She was also granted stock options for 12,500 shares of common stock at an exercise price of $8.78 per share, expiring on May 22, 2036, vesting in substantially equal monthly installments over 12 months or, if earlier, on the 2027 annual meeting date. After these awards, she holds 428,190 common shares directly and 496,940 shares indirectly through Robinhood II, LP, where she is general manager and disclaims beneficial ownership except for her pecuniary interest.
Immix Biopharma, Inc. reported that CEO and Chairman Ilya M. Rachman received a grant of stock options covering 500,000 shares of common stock. The options have an exercise price of $8.78 per share and expire on May 22, 2036.
These options were granted as compensation and do not represent an open-market purchase or sale. According to the terms, they vest in 48 equal monthly installments following the grant date, contingent on Dr. Rachman’s continued service with the company.
Immix Biopharma director Yekaterina Chudnovsky reported equity awards and updated holdings. She received 6,250 restricted stock units under the 2021 Equity Incentive Plan, vesting in full on the earlier of one year from grant or the 2027 annual stockholders meeting, subject to continued service.
She was also granted stock options for 12,500 shares of common stock at an exercise price of $8.78 per share, vesting in substantially equal monthly installments over 12 months or, if earlier, on the date of the 2027 annual meeting, contingent on continued board service. Following this Form 4, she holds 6,250 common shares directly and 12,500 options, and is associated with 3,241,076 shares held indirectly by GKCC, LLC, where she is the sole member and manager.
Hsu Jason reported acquisition or exercise transactions in this Form 4 filing.
Immix Biopharma, Inc. director Jason Hsu reported new equity compensation. He received 6,250 restricted stock units that vest in full on the earlier of one year from grant or the company’s 2027 annual meeting, subject to continued service. He was also granted a stock option for 12,500 shares at $8.78 per share, vesting in equal monthly installments over 12 months or, if earlier, on the 2027 annual meeting date. After these awards, he holds 899,250 common shares directly, plus additional indirect holdings through VERITAS LIBERABIT VOS, LLC and Signature Collection Properties, LLC, where he has voting and disposition rights but disclaims beneficial ownership except for his pecuniary interest.
Immix Biopharma director Jane Buchan reported equity compensation awards. She received 6,250 restricted stock units of common stock, bringing her direct common stock holdings to 28,705 shares after the grant.
She was also granted options to buy 12,500 shares of common stock at an exercise price of $8.78 per share, expiring on May 22, 2036. The RSUs vest in full on the earlier of one year from grant or the 2027 annual meeting, while the options vest in substantially equal monthly installments over 12 months, with any remaining portion vesting at the 2027 annual meeting, in each case subject to continued service.
Immix Biopharma, Inc. is raising capital through an underwritten public offering of 16,778,524 shares of common stock at $8.94 per share, for expected gross proceeds of $150 million and estimated net proceeds of about $140.65 million. The deal is being led by Morgan Stanley under an existing shelf registration statement and is expected to close around May 22, 2026, subject to customary conditions. Immix plans to use the cash mainly to fund development of its BCMA-targeted CAR-T therapy NXC-201, as well as for working capital and general corporate purposes, and believes this financing, together with existing cash, will fund operations into mid-2028.
Immix Biopharma is offering 16,778,524 shares of common stock at $8.94 per share. The prospectus supplement states net proceeds are estimated at approximately $140.65 million to fund NXC-201 clinical development, working capital and general corporate purposes. Shares outstanding immediately after the offering are shown as 69,790,616.
The filing notes clinical progress for CAR-T candidate NXC-201, including a reported 95% CR rate (19/20) among an early cohort in NEXICART-2 and regulatory designations such as RMAT, ODD and Breakthrough Therapy. Management retains broad discretion over use of proceeds and lock-up and stabilization arrangements are described.
Immix Biopharma reported interim Phase 2 NEXICART-2 data showing a 95% complete response (CR) rate, with 19 of the first 20 relapsed/refractory AL amyloidosis patients treated with CAR-T candidate NXC-201 achieving CR.
All minimal residual disease (MRD)-negative patients converted to CR, and all CRs occurred within one year of follow-up, with no relapses observed so far among CR patients. Seventeen of 20 patients showed rapid normalization of diseased light chains, with a median time to initial response of 7 days, and MRD-negativity at 10-5 was reached within 30 days for all MRD-negative patients.
NEXICART-2 is a fully enrolled 45-patient, multi-site U.S. Phase 2 trial with a potentially registrational design, and the next data update is expected in late September 2026. The company also plans a multi-center, randomized Phase 3 trial in newly diagnosed AL amyloidosis patients, targeted to start in the first half of 2027.
Janus Henderson Group plc reported beneficial ownership of 4,802,002 shares of Immix Biopharma, Inc. common stock, representing 9.1% of the class as disclosed on this Schedule 13G/A. The filing states the shares are held through multiple asset managers that exercise shared voting and dispositive power on behalf of managed portfolios.
The filing notes that the managed portfolios are the record holders entitled to dividends and sale proceeds, and that only Janus Henderson Biotech Innovation Master Fund Ltd. holds more than 5% with dividend/proceeds rights. The reporting person disclaims rights to receive dividends or sale proceeds for the asset managers described.
Immix Biopharma, Inc. reported a larger net loss as it continues to invest heavily in its cell therapy pipeline. For the three months ended March 31, 2026, net loss was $10.1 million, compared with $4.5 million a year earlier, driven by higher research and development and general and administrative expenses totaling $10.8 million.
Cash, cash equivalents and short-term investments were $90.6 million as of March 31, 2026, and total stockholders’ equity was $84.4 million. The company states this liquidity should fund operating and capital needs for at least 12 months from the filing of the quarterly report while it advances NXC‑201 and other programs.